Wegovy is made by which company — and what does that mean for you?

What exactly does Novo Nordisk make, and how does semaglutide fit in?

Novo Nordisk has specialised in hormone-based medicines since the 1920s, when the company was among the first to produce commercial insulin. Decades later, its researchers identified GLP-1 (glucagon-like peptide-1, a hormone the gut releases after eating) as a target worth developing into medicine. Semaglutide is the result: a synthetic version of that hormone, modified so it survives in the body long enough to be effective with a once-weekly injection rather than a daily one.

Wegovy is Novo Nordisk's brand name for semaglutide at the doses licensed specifically for weight management: starting at 0.25 mg and titrating through 0.5 mg, 1.0 mg and 1.7 mg up to a standard maintenance dose of 2.4 mg, all under prescriber direction. The MHRA subsequently approved a higher 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen approved on 14 April 2026. You can read the background on how semaglutide works as a medicine if you want the clinical detail behind the mechanism.

Novo Nordisk also makes Ozempic, which contains the same active molecule at lower doses, but with a licence for type 2 diabetes rather than weight management. The two products are not interchangeable. If you're curious about the company behind Wegovy and how it operates, that background is worth exploring if you have questions about which medicine is right for which condition.

Why does knowing who makes Wegovy matter when you're buying it?

The MHRA has issued repeated warnings about counterfeit weight-loss pens circulating online and through social media. Fake pens have been found to contain insulin rather than semaglutide, a potentially life-threatening substitution. In 2025, enforcement agencies seized roughly 20 million doses of illegally traded weight-loss medicines worth around £45 million, and the first illicit UK site producing counterfeit tirzepatide pens was dismantled in Northampton. The pattern for semaglutide counterfeits is similar.

Genuine Wegovy reaches patients through the licensed UK supply chain, which runs from Novo Nordisk through authorised wholesalers to GPhC-registered pharmacies. That chain matters because it is the only route that guarantees the pen in your hands is the product the manufacturer actually made. A pharmacy you can verify on the GPhC register (as you can with us) is a practical first check. Sellers offering Wegovy through social media, at prices far below the market, or without requiring a prescription are red flags regardless of what branding appears on the packaging.

The MHRA's public guidance on GLP-1 medicines is clear that these are prescription-only medicines assessed for clinical suitability, not cosmetic convenience. Report any suspect seller via the Yellow Card scheme.

What does Novo Nordisk's manufacturing scale mean for availability?

Supply shortages for Wegovy and Ozempic became a significant issue from 2022 onwards as demand outpaced Novo Nordisk's production capacity. The company has since invested billions in expanding its manufacturing sites in Denmark and the United States. UK supply has stabilised considerably since late 2024, though specific dose availability can vary at any given time.

This is one reason a prescriber's role matters beyond simply writing a prescription. Dose titration schedules, switching between pen formats, and managing periods when a particular strength is constrained all require clinical input. Pages exploring how long people typically use Wegovy and what happens when treatment pauses give a fuller picture of the ongoing relationship between manufacturer supply and clinical management.

For anyone considering treatment, the weight-loss treatment options overview explains how Wegovy sits alongside other licensed medicines available in the UK, including tirzepatide (Mounjaro), which comes from a different manufacturer, Eli Lilly, and works through a dual-receptor mechanism. If you want to understand which company owns Wegovy and what that means for how the medicine is developed and distributed, that page covers the corporate context clearly. If you want a clear answer to what company makes Wegovy and why that distinction matters, that page covers it in detail. The NHS medicines page for semaglutide gives the patient-level summary of how the medicine works and what to expect.

How does a clinically supervised private route to Wegovy actually work?

At nume, Wegovy is sourced exclusively through Novo Nordisk's authorised UK supply chain and dispensed from our GPhC-registered pharmacy. A consultation goes to a real prescriber (a GPhC-registered Independent Prescriber) the same day it's submitted. There is no algorithm making that call. If treatment is clinically appropriate and the order is placed before 12pm on a working day, the pen is dispatched the same day and arrives via DPD the next working day, in plain unbranded packaging with a tracking link on your phone before it's even left us.

Everything is included in a single transparent price: the consultation, the prescription, the medicine itself, and delivery. There are no subscriptions and no hidden fees. Our clinical team, including our prescriber Mostafa Damghani, oversees every step. If you have questions before starting, the FAQs cover the most common ones, or you can get in touch directly.

When you're ready, speak to our prescribers through a free consultation to see whether Wegovy is clinically suitable for you.